Chiasma

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

Chiasma headquartered in United States, North America, operates in the Biotechnology, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $62.3B in funding across 168 round(s). With a team of 51-100 employees, Chiasma is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Chiasma, raised $44.0M. Discover more about their projects, partnerships, and impact on our platform.